24 3 29 12 20 27 171 30 172 22 HLA-QC 175 30 HLA 182 183 30 HLA 190 30 192 30 HLA 194 29 HLA 196 29 HLA 198 J.J. van Rood 215 16 217 28 219 MHC 28 2 1 220 223 Major Histocompatibility Complex Official Journal of Japanese Society for Histocompatibility and Immunogenetics JSHI
Major Histocompatibility Complex 2017; 24 (3): 171 27 27 II 27 2018 9 1977 41 MHC MHC Precision Medicine HLA personalized medicine precision medicine 10 30 9 21 9 23 390 0815 3 10 1 TEL: 0263 33 3800 2 QCWS HLA 30 4 16 6 1 II 27 390 8621 3 1 1 TEL: 0263 37 2634 E-mail: jshi2018@shinshu-u.ac.jp 2018 1 QCWS 9 23 171
Major Histocompatibility Complex 2017; 24 (3): 172 174 30 26 26 30 1 30 27 30 4 1 45 1 10 5 2 1 5 1 2 3 2 1 2 3 4 5 6 7 MHC 8 3 172
30 MHC 2017; 24 (3) 9 4 1 45 3 1 30 2 28 e-mail: hlajimu@m.u-tokyo.ac.jp 1 A4 1 FAX e-mail 2 A4 2 3 3 3 1 4 A4 1 2 27 30 9 21 23 1 2 1 FAX e-mail 2 1 2 3 300 400 4 1 7 1 1 2 11 173
MHC 2017; 24 (3) 30 5 1 2 1 hlajimu@m.u-tokyo.ac.jp 2 3 MHC 6 7 e-mail: hlajimu@m.utokyo.ac.jp 174
Major Histocompatibility Complex 2017; 24 (3): 175 181 22 HLA-QC QC 30 22 HLA-QC 22nd.QCWS QCWS QC 1 30 2 28 30 4 9 14 DNA 30 4 30 5 30 6 8 HP CD 30 9 23 QCWS 2 QCWS 1 http://square.umin.ac.jp/jshi/qcws/index.html 2 QCWS jshiqcws@jrc.or.jp 3 QCWS FAX PDF 4 QCWS 6,000 1 hlajimu@m.u-tokyo.ac.jp 5 QCWS 30 2 28 3 QCWS QCWS QCWS QCWS QCWS 2,000 1 1 30 8 24 2 QCWS 2,000 3 QCWS QCWS 4 01720-6-72462 175
MHC 2017; 24 (3) 22 HLA-QC QCWS 22 QCWS QCWS FAX: 03 5802 8619 e-mail: hlajimu@m.u-tokyo.ac.jp 176
22 HLA-QC MHC 2017; 24 (3) 22 HLA-QC 1 HLA-QC 2 JSHI QCWS e-mail: jshiqcws@jrc.or.jp 3 1 6,000 22 HLA-QC 4 30 2 28 5 QCWS HLA-QC 22 HLA-QC E-mail a DNA-QC a QC b DNA-QC SSP b c QC c þ d þ d e HLA f 1 DNA-QC PCR-SSP SSP DNA b DNA-QC SSP 2 QCWS d e QC QC QC DNA-QC DNA-QC QC 3 QC QC QC 177
MHC 2017; 24 (3) 22 HLA-QC QCWS 1 QCWS 8 2 JSHI QCWS e-mail: jshiqcws@jrc.or.jp 3 1 2,000 22 HLA-QC 4 30 8 24 QCWS QCWS QCWS E-mail E-mail E-mail E-mail E-mail E-mail E-mail E-mail 178
22 HLA-QC MHC 2017; 24 (3) QCWS QCWS HLA 1 QCWS QCWS HP QCWS QCWS DNA DNA QCWS ID ID QCWS QCWS HP QCWS QCWS MHC QCWS QCWS QCWS QCWS QCWS QCWS QCWS 179
MHC 2017; 24 (3) 22 HLA-QC QCWS ID QCWS 14 QCWS ID QCWS QCWS QCWS DNA-QC -QC 1 6,000 QCWS 2,000 QCWS FAX 135-8521 1 67 QCWS FAX 03-5534-7588 e-mail jshiqcws@jrc.or.jp QCWS 2018 HLA HLA -QC DNA-QC DNA-QC 180
22 HLA-QC MHC 2017; 24 (3) QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QC DNA-QC QC QCWS 14thQCWS ID QCWS ID QCWS ID QCWS PDF 181
Major Histocompatibility Complex 2017; 24 (3): 182 30 HLA 30 9 23 9 00 11 00 27 390 0815 3 10 1 TEL 0263 33 3800 1 1 1 35 30 3 1 HLA 2 HLA HLA 3 HLA 182
Major Histocompatibility Complex 2017; 24 (3): 183 189 HLA 1 HLA 2 HLA HLA HLA 1 HLA Certified HLA Technologist JSHI 2 HLA HT/JSHI 2 HLA 1 Certified Director for Histocompatibility JSHI 2 DH/JSHI 3 HLA 2 1 HLA 3 4 HLA HLA HLA 5 HLA HLA 2 HLA 5 3 5 4 1 5 1 2 3 183
MHC 2017; 24 (3) HLA HLA 6 1 HLA 2 3 2 7 HLA 8 HLA 1 3 2 3 3 5 4 5 30 5 2 HLA 1 HLA 1 2 2 3 3 HLA 1 15,000 HLA 9 1 2 3 4 1 QC 5 6 HLA HLA HLA 184
HLA MHC 2017; 24 (3) HLA 10 HLA 2 HLA 3 4 5 HLA 11 HLA 1 5 30 5 2 2 1 3 5 QC 2 1 1 HLA 3 2 2 3 3 HLA 1 15,000 12 1 HLA 3 2 7 3 7 4 5 5 5 QC 6 5 70 10 2 1 4 2 2 3 185
MHC 2017; 24 (3) HLA 3 1 30,000 13 1 2 1 3 14 2 3 4 5 15 1 5 70 15 15 2 2 1 3 5 QC 2 1 1 5 2 2 3 3 1 30,000 16 15 1 11 1 HLA 2 11 2 3 3 186
HLA MHC 2017; 24 (3) 17 HLA 2 2 HLA 6 1 3 6 2 4 1 HLA 5,000 210,000 HLA 18 HLA 7 2 6 3 1 1,000 2 2,000 19 HLA 1 HLA 2 3 HLA 2 3 20 21 29 10 28 14 9 25 2 187
MHC 2017; 24 (3) HLA 14 HLA HLA 14 9 25 15 HLA HLA 19 9 11 HLA 20 9 21 188
HLA MHC 2017; 24 (3) 8 11 12 15 QC 15 10 10 7 10 7 10 7 7 5 5 3 5 3 2 5 5 2 5 5 10 HLA 5 HLA 5 10 HLA 189
Major Histocompatibility Complex 2017; 24 (3): 190 191 30 HLA HLA HLA 30 31 30 HLA 1 HLA 1 3 2 3 3 5 4 HLA 5 30 5 2 http://jshi.umin.ac.jp/certification/ 2 30 4 13 3 113 0033 7 3 1 03 5802 2907 03 5802 8619 4 1 HLA 1 2 1 2 6 2 3 82 190
30 HLA MHC 2017; 24 (3) http://jshi.umin.ac.jp/certification/ 2 5 2 1 5 5 15,000 01720-6-72462 6 9 2 QCWS 7 8 2 3 5 7 30 9 23 3 10 1 QC 9 4 7 8 1 27 2 191
Major Histocompatibility Complex 2017; 24 (3): 192 193 30 HLA 30 31 30 9 21 23 27 30 1 1 HLA 3 2 7 3 7 4 5 5 5 QC 6 HLA 5 70 10 3 http://jshi.umin.ac.jp/certification/ 2 30 4 13 7 3 113 0033 7 3 1 03 5802 2907 03 5802 8619 192
30 MHC 2017; 24 (3) 4 1 4 2 1 2 6 2 3 82 http://jshi.umin.ac.jp/certification/ 2 5 2 1 5 5 30,000 01720-6-72462 6 30 9 23 3 10 1 7 7 1 27 2 193
Major Histocompatibility Complex 2017; 24 (3): 194 195 30 HLA 25 2013 31 19 9 11 20 9 21 1 HLA 1 HLA 5 30 5 2 2 1 3 5 QC 1 HLA 5 70 15 15 2 2 1 3 5 QC http://jshi.umin.ac.jp/certification/ 2 30 4 13 6 194
30 HLA MHC 2017; 24 (3) 3 113 0033 7 3 1 03 5802 2907 03 5802 8619 4 1 HLA HLA 4 2 1 2 6 2 5 2 1 2 6 3 http://jshi.umin.ac.jp/certification/ 2 5 2 1 5 5 HLA 15,000 30,000 01720-6-72462 HLA 6 1 27 2 A4 195
Major Histocompatibility Complex 2017; 24 (3): 196 197 29 2017 10 29 2022 12 31 S17001 S17004 S17002 S17005 S17003 29 HLA 2017 10 29 2022 12 31 G17001 G17006 G17002 G17007 G17003 G17008 G17004 G17009 G17005 G17010 29 2017 10 29 2022 12 31 S02003 S02027 S02007 S02030 S02011 S02031 S02012 S02035 S02019 S12001 S02020 S12002 S02024 196
MHC 2017; 24 (3) 29 HLA 2017 10 29 2022 12 31 G02002 G02037 G02006 G02038 G02007 G02041 G02011 G02046 G02012 G02058 G02015 G07003 G02020 G07004 G02024 G07007 G02025 G12001 G02028 G12002 G02030 G12006 G02033 197
Major Histocompatibility Complex 2017; 24 (3): 198 214 平成 29 年度認定 HLA 検査技術者認定制度試験問題に関する報告 29 HLA 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 12 26 29 10 29 JMS 4 2 84 66 8 9 12 4 HLA 3 40 3 5 18 5 10 13 11 50 26.6 5.3 16.9% 94.0% 53.3% 19.6% 13 28.9% 82.1% 47.8% 17.1% 28 50 22.4 5.9 8.2% 78.7% 44.8% 19.1% 29 26 50 26.6 6.2 7.8% 94.1% 53.2% 22.9% 27 49 24.4 5.0 7.8% 94.1% 53.2% 22.9% 29 29 40% 198
29 HLA MHC 2017; 24 (3) 平成 29 年度認定 HLA 検査技術者認定制度試験問題 正解と難問の解説 40% 13 1 36 20% 5 40% 29 9 28 512 254 258 2 1 a e 1 2 3 4 5 a 1, 2 b 2, 3 c 1, 4 d 3, 4 e 1, 5 正解 :c 45.2% b 2 HLA a e a HLA b HLA-B c HLA I d HLA e HLA-DR T 正解 :e 54.8% a 3 a e a 46 b 1 2 199
MHC 2017; 24 (3) 29 HLA c HLA 6 d NK KIR ULBP/RAET e 正解 :c 46.4% a, d 4 a e a b c d e 正解 :c 50.0% a 5 HLA I a e 1 MHC MHC 2 HLA-A MHC 3 HLA-B MHC 4 HLA-C MHC 5 HLA-G MHC a 1, 2, 3 b 1, 2, 5 c 1, 4, 5 d 2, 3, 4 e 3, 4, 5 正解 :d 81.0% a 6 HLA a e a HLA dbsnp b HLA DDBJ c HLA IMGT d HLA HapMap e HLA OMIM 正解 :c 63.1% b 7 HLA I a e a 200
29 HLA MHC 2017; 24 (3) b c d e 正解 :b 63.1% a 8 HLA HLA a e a HLA-DR B b HLA-A c HLA I NK d HLA MICA T e HLA-G 正解 :c 54.8% d, e 9 HLA I a e a 2 b c 9 10 d e CD8 正解 :a 54.8% c 10 MICA a e a I b KIR c NK T d e microrna 正解 :b 29.8% a, c, d, e MICA NK CD8 T T CD94/NKG2D KIR CD4 T CD94/NKG2D 201
MHC 2017; 24 (3) 29 HLA microrna mir25-93-106b microrna-20a MICA 11 HLA I 2 a e a CD1a b HLA-F c MICA d MR1 e HFE 正解 :c 25.0% b, e MICA 2 2 12 HLA a e 1 HLA II 2 HLA I II 3 HLA I II 4 HLA II 5 TAP a 1, 2 b 1, 3 c 2, 3 d 3, 4 e 4, 5 正解 :a 22.6% c TAP HLA I HLA I / HLA II HLA I HLA I 202
29 HLA MHC 2017; 24 (3) HLA I II T T 4 13 HLA a e a HLA b c d e HLA 正解 :c 39.3% b T B somatic recombination rearrangement HLA 14 HLA a e a II b I c d TAP1 TAP2 e B II 正解 :d 61.9% a, b 15 NK NKG2 a e a MIC b MIC c III d CD1d e I HLA-A,-B,-C 正解 :a 21.4% b, e MIC NKG2 NKG2D/CD94 DAP10 ULBP RAE-1 NKG2D/CD94 NKG2 203
MHC 2017; 24 (3) 29 HLA NKG2A/CD94 NKG2C/CD94 HLA-E DAP12 I CD1d NKT T V I NK KIR KIR3DS KIR DS 16 a e a T Th1/Th2 b c T d NK e B CD40 正解 :c 60.7% e 17 T a e 1 T 2 GVHD T 3 T CD4 T CD8 T 4 HLA T 5 HLA T a 1, 2 b 2, 3 c 2, 5 d 3, 4 e 4, 5 正解 :e 52.4% d 18 T a e 1 2 3 MHC I- CD4 4 T MHC- 5 T CD4 CD8 a 1, 2, 3 b 1, 2, 5 c 1, 4, 5 d 2, 3, 4 e 3, 4, 5 正解 :c 66.7% b 19 MHC T TCR TCR T a e a b 204
29 HLA MHC 2017; 24 (3) c TCR d T e T 正解 :d 28.9% c, e affinity maturation B somatic hypermutation T TCRT MHC TCR T T T MHC T B 20 a e a b B 1 99% c d 1980 e BCG 正解 :d 82.1% e 21 a e a T b HLA c HLA T d HLA T e 正解 :d 54.2% b, c 22 a e a b c HCV 205
MHC 2017; 24 (3) 29 HLA d e 正解 :d 28.9% c HCV HCV 23 a e a b c d e 正解 :b 63.9% d 24 HLA T GVHD a e 1 HLA 2 3 4 5 T a 1, 2, 3 b 2, 3, 4 c 1, 2, 5 d 3, 4, 5 e 2, 4, 5 正解 :b 30.1% a, e HLA GVHD T 1 5 25 a e a b One haplotype c HLA HLA 206
29 HLA MHC 2017; 24 (3) d e a d 正解 :a 51.2% e 26 a e a CCI 1 3,000/μL b HLA c HLA d HLA HLA ABO e HLA HLA 正解 :d 81.0% a 27 HLA a e a HLA b HLA c HLA d HLA ABO e HLA 正解 :a 65.5% d 28 HLA a e a I HLA-DRB1*15:02 b HLA-DPB1*09:01 c HLA-B*53:01 d HLA-A*27:01 e HLA-DRB1*04:06 正解 :e 31.0% a, c, d HLA I DRB1*04:05 DRB1*15:02 I 207
MHC 2017; 24 (3) 29 HLA DRB1*04:05 B*51:01 HLA-B27 B*27:04 B*27:05 B*27:04 B*27:05 B*27:06 B*27:09 29 HLA a e a b c HLA d e 正解 :c 71.1% b 30 HLA a e 1 HLA 2 HLA 3 HLA 4 HLA 5 HLA a 1, 3 b 1, 4 c 2, 3 d 3, 4 e 3, 5 正解 :b 41.0% d 31 HLA a e a b c d e 2 正解 :c 33.7% e genome-wide association study; GWAS HLA HLA HLA 208
29 HLA MHC 2017; 24 (3) GWAS 32 a e a ABO O B b Rh Rho(+) Rho(-) c HLA A*24, A*26 A*02, A*24 d TH01 6 9 7 8 e MN MN M 正解 :d 83.3% b 33 a e a 2010 b 2014 10 1 c ES ips d HLA e 正解 :a 30.1% 2015 2016 12.5% 21.3% c 2014 393,745 47,322 2014 100 3500 21 1 ES ips HLA 34 ips a e a ips T b ips c ips d ips e ips HLA I 正解 :d 48.2% b 35 a e 209
MHC 2017; 24 (3) 29 HLA a MHC b c 1 d e 2000 正解 :d 66.3% a 36 a e a b c d e 正解 :e 16.9% a, c 37 HLA a e 1 HLA DNA 2 LCT HLA 3 SSOP HLA 1 2 4 LCT CDC HLA 5 LCT HLA a 1, 2 b 1, 3 c 2, 4 d 2, 5 e 4, 5 正解 :a 56.0% c 38 HLA a e 1 a b a b 2 a a+b a 3 a+b a+c a b c 4 a+b a+c a 5 null allele 210
29 HLA MHC 2017; 24 (3) a 1, 2 b 2, 3 c 2, 4 d 3, 5 e 4, 5 正解 :b 41.7% a, c, e 39 a e a b c d HLA e HLA 正解 :d 22.6% b, c HLA HLA 40 HLA a e 1 HLA 2 3 HLA 4 HLA DNA 5 HLA HLA a 1, 2 b 2, 3 c 2, 4 d 3, 4 e 4, 5 正解 :b 61.9% d 41 MLR a e a b c d e 正解 :e 84.5% a 42 MLR a e 211
MHC 2017; 24 (3) 29 HLA a MLR CD4 HLA-DR T b MLR T c MLR B d MLR T e MLR T T IL-2 IFN- 正解 :d 45.8% a, b, c, e 43 HLA a e 1 RFLP 2 SSP 3 SBT HLA 4 SSOP 5 SSCP a 1, 2 b 2, 3 c 3, 4 d 3, 5 e 4, 5 正解 :b 75.0% a, c 44 PCR DNA a e a PCR DNA b PCR DNA c DNA A260/A280 1.8 d DNA 260 nm e DNA PCR 正解 :b 77.4% d 45 DNA a e PCR 1 2 a PCR-SSO b PCR-SSP c PCR-SSCP d PCR-RFLP e PCR-SBT 正解 :b 212
29 HLA MHC 2017; 24 (3) 70.2% d 46 DNA a e 1 DNA 2 PCR PCR 3 PCR 4 PCR 5 PCR a 1, 3 b 2, 4 c 1, 5 d 3, 4 e 4, 5 正解 :b 94.0% e 47 DTT a e 1 9 μl 50 mm DTT 1 μl 2 1 μl 50 mm DTT 9 μl 3 37 C 30 IgG 4 37 C 30 IgM 5 4 C 30 IgG a 1, 3 b 1, 4 c 2, 3 d 4, 5 e 1, 5 正解 :b 79.8% a 48 a e a SNP b Y c Insertion-deletion d Variable number of tandem repeats VNTR e 正解 :b 40.2% a, c, d 49 a e a CDC HLA b FCXM HLA c FCXM T I B II d LCT I e CDC 213
MHC 2017; 24 (3) 29 HLA 正解 :e 59.0% b, c 50 100 HLA HLA-DRB1*09:01 a e a 0.22 b 0.50 c 0.78 d 1.28 e 2.00 HLA-DRB1*09:01 HLA-DRB1*09:01 40 60 25 75 正解 :e 57.8% b, c 214
Major Histocompatibility Complex 2017; 24 (3): 215 216 J.J. van Rood HLA JJ. van Rood 1973 HLA HLA II 40 50 van Rood Terasaki van Rood Van Rood Dausset HLA-A2 Rose Payne LA HLA-A HLA Van Rood HLA-B 4a 4b 1) 1959 Vox Sanguinis 2) 39 C 6 500 1000 213 1959 van Rood 1970 HLA-D HLA I LCT SD serologically defined HLA-D LD LD LCT LD B van Rood B LCT B HLA I LCT B HLA- I 215
MHC 2017; 24 (3) J.J. van Rood 3) HLA-D HLA-D HLA-DR D relatedhla- DQ B HLA II van Rood HLA van Rood 1) J.J. van Rood and A. van Leewen: Leukocyte grouping. A method and its application. J. Clin. Invest. 42: 1382, 1963. 2) J.J. van Rood, A. van Leewen and J.G. Earnisse: Leucocyte antibodies in sera of pregnant women. Vox Sang. 4: 427, 1959. 3) J.J. van Rood, A. van Leewen, J.J. Keuning and A.B. van Oud Alblas: The serological recognition of the human MLC determinants using a modified cytotoxicity technique. Tissue Antigens. 5: 73, 1975. 216
Major Histocompatibility Complex 2017; 24 (3): 217 218 16 HLA 16 30 3 3 7 2 4 43 JR 350 m TEL 06 6962 7001 2000 1000 3000 30 1 20 A4 1 MS 12 A4 1 16 yuketsu@med.kindai.ac.jp Windows Power Point Mac Power Point 30 2 24 10 2 1 2 8 30 10 00 10 30 11 00 11 00 12 00 12 00 13 00 13 15 14 45 15 00 16 00 16 00 17 00 * yuketsu@med.kindai.ac.jp 217
MHC 2017; 24 (3) XXXX XXXX 1) 2) XXX 1) XX 2) 1 20 mm 25 mm 2 1 Microsoft Word 2 MS 12 340 36 3 1 2 3 4 5 1 Microsoft Excel 2 218
219
Major Histocompatibility Complex 2017; 24 (3): 220 222 MHC 28 2 1 I MHC 1964 18 2013 ES ips 2006 JST J-STAGE II 1 400 30 12 1 1 Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR Email 2 1 FAX E-mail Susceptibility gene for non-obstructive azoospermia in the HLA class II region: correlations with Y chromosome microdeletion and spermatogenesis. Tetsuya Takao 1), Akira Tsujimura 1), Masaharu Sada 2), Reiko Goto 2), Minoru Koga 3), Yasushi Miyagawa 1), Kiyomi Matsumiya 1), Kazuhiko Yamada 2), Shiro Takahara 1) 220
MHC 2017; 24 (3) 1) Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 2) Department of Regenerative Medicine, National Cardiovascular Center, Suita, Osaka, Japan 3) Department of Urology, Osaka Central Hospital, Osaka, Japan FlowPRA HLA 1) 1) 2) 2) 3) 1) 2) 3) 3 1 2 400 250 words 5 cm, ml, g, Kg, pg, μl, %, C HLA-DRB1 4 2 2 250 words 5 3 Introduction Materials and Methods Results Discussion References cm, ml, g, Kg, pg, μl, %, C HLA-DRB1 5 3 LCT Lymphocyte cytotoxicity test 6 3 4 et al. 1. Shi Y, Yoshihara F, Nakahama H, et al.: A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis. Regulatory Peptides 127(1 3): 233 238, 2005. 2. Tongio M, Abbal M, Bignon JD, et al.: ASH#18: HLA-DPB1. Genetic diversity of HLA Functional and Medical Implication (ed. Charron D), Medical and Scientific International Publisher, p. 134 136, 1997. 3. IVIG 1 17(1): 36 40, 2005. 221
MHC 2017; 24 (3) 4. 6 Medical View p. 120 125 2000 III 1 400 15 6 1 1 Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR Email 2 1 FAX E-mail 3 2 200 words 3 3 3 3 IV V 565 0871 2 2 J8 MHC E-mail: tanimoto@att.med.osaka-u.ac.jp Tel: 06 6879 3746 Fax: 06 6879 3749 30 5 10 20 250 words 400 words 5 1 15 5 10 200 words 3 1 20 30 400 5 1 222
MHC 2017; 24 (3) MHC 24 3 20 web 5 MHC PDF MHC HLA HLA HLA HLA http://square.umin.ac.jp/jshi/index.html http://jshi.umin.ac.jp/index.html 23 24 24 5 URL http://jshi.umin.ac.jp/ URL http://jshi. umin.ac.jp/ Email:jshi@nacos.com 113 0033 7 3 1 Tel Fax 03 5802 2907 E-mail hlajimu@m.u-tokyo.ac.jp 602 8048 075 415 3662 FAX 075 415 3661 Email jshi@nacos.com 223